Loading...

Buy Full Version
"Anti-Rheumatics Market"

Let us help you !

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Anti-Rheumatics Market by Drug Class (Disease Modifying Anti-Rheumatic Drugs (DMARD's), Nonsteroidal Anti-Inflammatory Drugs (NSAID's), Corticosteroids, Uric Acid Drugs, and Others), Type (Prescription-Based Drugs and Over-the-Counter Drugs): Global Opportunity Analysis and Industry Forecast, 2019–2026

LI_206289
Pages: 202
Jan 2020 | 90 Views
 
Author(s) : Sagar Mukhekar , Onkar Sumant
Tables: 108
Charts: 62
 

The global anti-rheumatics market accounted for $57,229 million in 2018 and is expected to reach $71,934 million by 2026, registering a CAGR of 2.9% from 2019 to 2026. 

Rheumatoid arthritis is a medical condition, which is marked by the presence of warm, swollen, and painful joints. The condition mostly affects both wrists and hands of a person. This medical condition is associated with pain, which worsens over time. The treatment for this condition is achieved by using different drugs, which are known as anti-rheumatics. Furthermore, these drugs are also used to modify the course of the medical condition. For instance, disease-modifying anti-rheumatics drugs are a type of anti-rheumatics drugs that slow down the progression of this disease. Moreover, drugs such as non-steroidal anti-inflammatory drugs are also used in the treatment for rheumatoid arthritis.    

Anti-Rheumatics Market

Get more information on this report : Request Sample Pages

The major factors that fuel the growth of the global anti-rheumatics market include rise in incidence of rheumatoid arthritis and surge in geriatric population across the globe. In addition, increase in incidence of obesity worldwide is another major factor that drives the growth of the anti-rheumatics market. However, side effects associated with the medication and higher cost of biologics & biosimilars restrain the growth of the market. On the contrary, developments in the field of biosimilars and novel biologics are anticipated to offer profitable opportunities for the growth of the anti-rheumatics market.

Anti-rheumatics Market Segmentation  

The anti-rheumatics market size is studied on the basis of drug class, type, and region to provide a detailed assessment of the market. On the basis of drug class, it is divided into disease modifying anti-rheumatics drugs (DMARD's), nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, uric acid drugs, and others. By type, it is divided into prescription-based drugs and over-the-counter drugs. By region, the anti-rheumatics market size is analyzed across North America (the U.S., Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA). 

Segment Review

According to drug class, the disease modifying anti-rheumatics drugs occupied the largest anti-rheumatics market share in 2018, owing to their action on the medical condition. For instance, DMARDs act on the underlying medical condition rather than acting on the symptoms. Furthermore, the nonsteroidal anti-inflammatory drugs segment is expected to register the fastest growth during the forecast period, owing to the surge in incidences of rheumatoid arthritis associated with pain in the joints.

Anti-Rheumatics Market
By Drug Class

Your browser does not support the canvas element.

Disease Modifying Anti-rheumatic Drugs segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By type, the prescription-based drugs segment occupied the largest share, owing to rise in the number of specialized hospitals worldwide as the medical condition requires treatment from a specialized medical professional. Furthermore, the over-the-counter drugs segment is expected to exhibit the fastest growth rate during the forecast period, owing to surge in awareness related to treatment options available for rheumatoid arthritis. Moreover, easy availability of NSAIDs over-the-counter is another major factor that contributes to the growth of the anti-rheumatics market.  

Anti-Rheumatics Market
By Type

Your browser does not support the canvas element.

Prescription based drugs segment holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By region, North America accounted for the major anti-rheumatics market share in 2018 and is expected to continue this trend owing to, easy availability of the anti-rheumatics. Moreover, surge in geriatric population in the region is another major factor that fuels the growth of anti-rheumatics market in North America. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period, owing to surge in awareness related to the use of anti-rheumatics. The constantly evolving life science industry drives the growth of the market in the developing economies such as India, China, and Malaysia.

Anti-Rheumatics Market
By Region

2026
Asia-Pacific 
North America
Europe
LAMEA

Asia-Pacific region would exhibit the highest CAGR of 3.7% during 2019-2026.

Get more information on this report : Request Sample Pages

The global anti-rheumatics market is highly competitive and the prominent players in the market have adopted various strategies to garner maximum market share. These include collaboration, product launch, partnership, and acquisition. Major players operating in the market include Pfizer, Inc., Johnson & Johnsons, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Celegene Corporations, MedImmune, LLC, Takeda Pharmaceutical Company Ltd., Biogen Inc., Celltrion Inc., and Amgen Inc.

Key Benefits for Stakeholders:

  • This report entails a detailed quantitative analysis along with the current global anti-rheumatics market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
  • The anti-rheumatics market forecast is studied from 2019 to 2026. 
  • The market size and estimations are based on comprehensive analysis of key developments in the industry. 
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments:

By Drug Class

  • Disease Modifying Anti-rheumatics Drugs (DMARD's)
  • Nonsteroidal Anti-inflammatory Drugs (NSAID's)
  • Corticosteroids
  • Uric Acid Drugs
  • Others

By Type

  • Prescription-Based Drugs
  • Over-the-Counter Drugs

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany 
    • France 
    • UK 
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan 
    • China 
    • India 
    • Australia 
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil 
    • Saudi Arabia 
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments

1.2.1. List of key players profiled in the report

1.3. Research methodology

1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Top player positioning

3.2.1. Top investment pockets

3.3. Key forces shaping anti-rheumatics industry/market
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Surge in geriatric population across the globe
3.4.1.2. Surge in healthcare expenditure worldwide
3.4.1.3. Rise in prevalence of rheumatoid arthritis across  the globe

3.4.2. Restraint

3.4.2.1. Patent expirations of blockbuster drugs

3.4.3. Opportunity

3.4.3.1. High growth potential in developing economies

3.4.4. Impact Analyses

CHAPTER 4: ANTI-RHEUMATICS MARKET, BY DRUG CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Disease Modifying Anti-Rheumatic Drugs

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis by country

4.3. Nonsteroidal Anti-inflammatory Drugs

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis by country

4.4. Corticosteroids

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis by country

4.5. Uric Acid Drugs

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis by country

4.6. Others

4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis by country

CHAPTER 5: ANTI-RHEUMATICS MARKET, BY TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Prescription-Based Drugs

5.2.1. Market size and forecast, by region
5.2.2. Market analysis by country

5.3. Over-the-Counter Drugs

5.3.1. Market size and forecast, by region
5.3.2. Market analysis by country

CHAPTER 6: ANTI-RHEUMATICS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends and opportunities
6.2.2. Market analysis, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. market size and forecast, by drug class
6.2.2.1.2. U.S. market size and forecast, by type

6.2.2.2. Canada

6.2.2.2.1. Canada market size and forecast, by drug class
6.2.2.2.2. Canada market size and forecast, by type

6.2.2.3. Mexico

6.2.2.3.1. Mexico market size and forecast, by drug class
6.2.2.3.2. Mexico market size and forecast, by type

6.2.3. North America market size and forecast, by drug class
6.2.4. North America market size and forecast, by type

6.3. Europe

6.3.1. Key market trends and opportunities
6.3.2. Market analysis, by country

6.3.2.1. Germany

6.3.2.1.1. Germany market size and forecast, by drug class
6.3.2.1.2. Germany market size and forecast, by type

6.3.2.2. France

6.3.2.2.1. France market size and forecast, by drug class
6.3.2.2.2. France market size and forecast, by type

6.3.2.3. UK

6.3.2.3.1. UK market size and forecast, by drug class
6.3.2.3.2. UK market size and forecast, by type

6.3.2.4. Italy

6.3.2.4.1. Italy market size and forecast, by drug class
6.3.2.4.2. Italy market size and forecast, by type

6.3.2.5. Rest of Europe

6.3.2.5.1. Rest of Europe market size and forecast, by drug class
6.3.2.5.2. Rest of Europe market size and forecast, by type

6.3.3. Europe market size and forecast, by drug class
6.3.4. Europe market size and forecast, by type

6.4. Asia-Pacific

6.4.1. Key market trends and opportunities
6.4.2. Market analysis, by country

6.4.2.1. Japan

6.4.2.1.1. Japan market size and forecast, by drug class
6.4.2.1.2. Japan market size and forecast, by type

6.4.2.2. China

6.4.2.2.1. China market size and forecast, by drug class
6.4.2.2.2. China market size and forecast, by type

6.4.2.3. India

6.4.2.3.1. India market size and forecast, by drug class
6.4.2.3.2. India market size and forecast, by type

6.4.2.4. Rest of Asia-Pacific

6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by drug class
6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by type

6.4.3. Asia-Pacific market size and forecast, by drug class
6.4.4. Asia-Pacific market size and forecast, by type

6.5. LAMEA

6.5.1. Key market trends and opportunities
6.5.2. Market analysis, by country

6.5.2.1. Brazil

6.5.2.1.1. Brazil market size and forecast, by drug class
6.5.2.1.2. Brazil market size and forecast, by type

6.5.2.2. South Africa

6.5.2.2.1. South Africa market size and forecast, by drug class
6.5.2.2.2. South Africa market size and forecast, by type

6.5.2.3. Saudi Arabia

6.5.2.3.1. Saudi Arabia market size and forecast, by drug class
6.5.2.3.2. Saudi Arabia market size and forecast, by type

6.5.2.4. Rest of LAMEA

6.5.2.4.1. Rest of LAMEA market size and forecast, by drug class
6.5.2.4.2. Rest of LAMEA market size and forecast, by type

6.5.3. LAMEA market size and forecast, by drug class
6.5.4. LAMEA market size and forecast, by type

CHAPTER 7: COMPANY PROFILES

7.1. AbbVie Inc.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments

7.2. Amgen Inc.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance

7.3. BRISTOL-MYERS SQUIBB COMPANY

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance

7.4. Eli Lilly And Company

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments

7.5. F. HOFFMANN-LA ROCHE LTD.

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance

7.6. Johnson & Johnson

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance

7.7. Merck & Co., Inc

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance

7.8. Novartis AG

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments

7.9. Pfizer Inc.

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments

7.10. UCB S.A.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments

 LIST OF TABLES

TABLE 01. GLOBAL ANTI-RHEUMATICS MARKET, BY DRUG CLASS, 2018-2026 ($MILLION )
TABLE 02. DISEASE MODIFYING ANTI-RHEUMATIC DRUGS  ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. NONSTEROIDAL ANTI-INFLAMMATORY DRUGS  ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. CORTICOSTEROIDS ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. URIC ACID DRUGS ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. OTHERS ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. GLOBAL ANTI-RHEUMATICS MARKET, BY TYPE, 2018-2026 ($MILLION )
TABLE 08. PRESCRIPTION-BASED ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. OVER-THE-COUNTER ANTI-RHEUMATICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 10. ANTI-RHEUMATICS MARKET, BY REGION, 2018-2026 ($MILLION )
TABLE 11. NORTH AMERICA ANTI-RHEUMATICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 12. U.S. ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 13. U.S. ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 14. CANADA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 15. CANADA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 16. MEXICO ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 17. MEXICO ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 18. NORTH AMERICA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 19. NORTH AMERICA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026($MILLION)
TABLE 20. EUROPE ANTI-RHEUMATICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 21. GERMANY ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 22. GERMANY ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 23. FRANCE ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 24. FRANCE ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 25. UK ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 26. UK ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 27. ITALY ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 28. ITALY ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 29. REST OF EUROPE ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 30. REST OF EUROPE ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 31. EUROPE ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 32. EUROPE ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026($MILLION)
TABLE 33. ASIA-PACIFIC ANTI-RHEUMATICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 34. JAPAN ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 35. JAPAN ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 36. CHINA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 37. CHINA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 38. INDIA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 39. INDIA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 40. REST OF ASIA-PACIFIC ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 41. REST OF ASIA-PACIFIC ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 42. ASIA-PACIFIC ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 43. ASIA-PACIFIC ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026($MILLION)
TABLE 44. LAMEA ANTI-RHEUMATICS MARKET REVENUE, BY COUNTRY, 2019–2026 ($MILLION)
TABLE 45. BRAZIL ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 46. BRAZIL ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 47. SOUTH AFRICA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 48. SOUTH AFRICA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 49. SAUDI ARABIA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 50. SAUDI ARABIA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 51. REST OF LAMEA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026 ($MILLION)
TABLE 52. REST OF LAMEA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026 ($MILLION)
TABLE 53. LAMEA ANTI-RHEUMATICS MARKET REVENUE, BY DRUG CLASS, 2019–2026($MILLION)
TABLE 54. LAMEA ANTI-RHEUMATICS MARKET REVENUE, BY TYPE, 2019–2026($MILLION)
TABLE 55. ABBVIE: COMPANY SNAPSHOT
TABLE 56. ABBVIE: OPERATING SEGMENTS
TABLE 57. ABBVIE: PRODUCT PORTFOLIO
TABLE 58. AMGEN: COMPANY SNAPSHOT
TABLE 59. AMGEN: OPERATING SEGMENTS
TABLE 60. AMGEN: PRODUCT PORTFOLIO
TABLE 61. BMS: COMPANY SNAPSHOT
TABLE 62. BMS: OPERATING SEGMENTS
TABLE 63. BMS: PRODUCT PORTFOLIO
TABLE 64. LILLY : COMPANY SNAPSHOT
TABLE 65. LILLY: OPERATING SEGMENTS
TABLE 66. LILLY: PRODUCT PORTFOLIO
TABLE 67. ROCHE: COMPANY SNAPSHOT
TABLE 68. ROCHE: OPERATING SEGMENTS
TABLE 69. ROCHE: PRODUCT PORTFOLIO
TABLE 70. J&J: COMPANY SNAPSHOT
TABLE 71. J&J: OPERATING SEGMENTS
TABLE 72. JOHNSON & JOHNSON: PRODUCT PORTFOLIO:
TABLE 73. MERCK: COMPANY SNAPSHOT
TABLE 74. MERCK: OPERATING SEGMENTS
TABLE 75. MERCK: PRODUCT PORTFOLIO
TABLE 76. NOVARTIS: COMPANY SNAPSHOT
TABLE 77. NOVARTIS: OPERATING SEGMENTS
TABLE 78. NOVARTIS: PRODUCT PORTFOLIO
TABLE 79. PFIZER: COMPANY SNAPSHOT
TABLE 80. PFIZER: OPERATING SEGMENTS
TABLE 81. PFIZER: PRODUCT PORTFOLIO
TABLE 82. UCB: COMPANY SNAPSHOT
TABLE 83. UCB: PRODUCT SEGMENTS
TABLE 84. UCB: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. GLOBAL ANTI-RHEUMATICS MARKET SEGMENTATION
FIGURE 02. TOP PLAYER POSITIONING, 2018
FIGURE 03. TOP INVESTMENT POCKETS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIER
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. LOW THREAT OF NEW ENTRANT
FIGURE 09. WORLD POPULATION AGED 65 AND OVER (%)
FIGURE 10. IMPACT ANALYSES, ANTI-RHEUMATICS MARKET
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ANTI-RHEUMATICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF NONSTEROIDAL ANTI-INFLAMMATORY ANTI-RHEUMATICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDS ANTI-RHEUMATICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF URIC ACID DRUGS ANTI-RHEUMATICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF OTHERS ANTI-RHEUMATICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF PRESCRIPTION-BASED ANTI-RHEUMATICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF OVER-THE-COUNTER ANTI-RHEUMATICS MARKET, BY COUNTRY, 2018 & 2026 (%)
FIGURE 18. U.S. ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 19. CANADA ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 20. MEXICO ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 21. COMPARISON OF MALE GERIATRIC POPULATION IN EUROPEAN COUNTRIES, 2017 (MILLION)
FIGURE 22. GERMANY ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 23. FRANCE ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 24. UK ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 25. ITALY ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 26. REST OF EUROPE ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 27. JAPAN ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 28. CHINA ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 29. INDIA ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 30. REST OF ASIA-PACIFIC ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 31. BRAZIL ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 32. SOUTH AFRICA ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 33. SAUDI ARABIA ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 34. REST OF LAMEA ANTI-RHEUMATICS MARKET, 2018-2026 ($MILLION)
FIGURE 35. ABBVIE: NET SALES, 2016–2018 ($MILLION)
FIGURE 36. ABBVIE: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 37. ABBVIE: REVENUE SHARE BY REGION, 2018(%)
FIGURE 38. AMGEN: NET SALES, 2017–2018 ($MILLION)
FIGURE 39. AMGEN INC.: REVENUE SHARE BY REGIONS, 2018 (%)
FIGURE 40. BMS: NET SALES, 2016–2018 ($MILLION)
FIGURE 41. BMS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 42. LILLY: NET SALES, 2016–2018 ($MILLION)
FIGURE 43. LILLY: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 44. LILLY: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 45. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 46. ROCHE: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 47. ROCHE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 48. J&J: NET SALES, 2016–2018 ($MILLION)
FIGURE 49. J&J: REVENUE SHARE BY SEGMENTS, 2018(%)
FIGURE 50. J&J: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 51. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 52. MERCK.: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 53. MERCK: REVENUE SHARE BY REGION, 2018(%)
FIGURE 54. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
FIGURE 55. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 56. NOVARTIS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 57. PFIZER: NET SALES, 2016–2018 ($MILLION)
FIGURE 58. PFIZER: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 59. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 60. UCB: NET SALES, 2016–2018 ($MILLION)
FIGURE 61. UCB: REVENUE SHARE BY SEGMENTS, 2018 (%)
FIGURE 62. UCB: REVENUE SHARE BY REGION, 2018 (%)

 
 

Rheumatoid arthritis is a chronic inflammatory medical condition in which the body’s immune system attacks its own tissues such as joints. This leads to painful swelling in the joints of a patient. The drugs used for the treatment of rheumatoid arthritis are called anti-rheumatics. Furthermore, there are different types of drugs that are used to treat this condition. For instance, disease modifying anti-rheumatic drugs are employed to modify the course of the medical condition. Similarly, other types of drugs such as nonsteroidal anti-inflammatory drugs are employed to treat the pain associated with the condition.  

The utilization of anti-rheumatics has witnessed a significant growth, owing to surge in incidences of rheumatoid arthritis. The other factors that propel the utilization of different anti-rheumatics include increase in geriatric population across the globe, as the medical condition is more predisposed in elderly patients. Conversely, high price of the biologicals is a major factor that hinders the growth of the market. Whereas, surge in awareness related to the use of anti-rheumatics is expected to present lucrative opportunities for the key players during the forecast period.

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subscription @ $699 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Anti-Rheumatics market is $57228.5 million in 2018.

A. The forcast period for Anti-Rheumatics market is 2019 to 2026

A. The market value of Anti-Rheumatics market in 2019 is $58888.1 million

A. The base year is 2018 in Anti-Rheumatics market

A. The top companies such as, Eli Lilly And Company, Abbvie Inc., Pfizer Inc., UCB S.A., and Johnson & Johnson, held a high market position in 2018. This is due to the strong geographical presence of these key players across the globe.

A. Nonsteroidal anti-inflammatory drug segment is the most influencing segment growing in the Anti-Rheumatics market. This is due to the role NSAIDs play in in managing joint pain in the patients suffering from rheumatoid arthritis.

A. The key trend in the Anti-Rheumatics market is the rise in prevalence of rheumatoid arthritis across the globe. This leads to surge in demand for anti-rheumatics required for the treatment of rheumatoid arthritis which in turn fuels the growth of the market.

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 4.6%. This is due to surge in awareness related to use of anti-rheumatics in the treatment of rheumatoid arthritis.

image image image image image image image image image image image image image image image image image image image
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Anti-Rheumatics Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $0.00
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample